Fresenius Medical Care (NYSE:FMS) Shares Gap Up to $20.18

Fresenius Medical Care AG (NYSE:FMS) gapped up prior to trading on Friday . The stock had previously closed at $20.18, but opened at $20.99. Fresenius Medical Care shares last traded at $21.08, with a volume of 108,463 shares traded.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Truist Financial lowered their price objective on shares of Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating on the stock in a research report on Wednesday, July 31st. StockNews.com began coverage on shares of Fresenius Medical Care in a report on Saturday. They set a “strong-buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $22.00.

Fresenius Medical Care Stock Up 4.5 %

The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09. The stock has a market cap of $12.38 billion, a price-to-earnings ratio of 23.70, a P/E/G ratio of 1.09 and a beta of 0.90. The business has a fifty day moving average of $19.45 and a 200 day moving average of $19.88.

Fresenius Medical Care (NYSE:FMS) last released its quarterly earnings results on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.38. The business had revenue of $5.13 billion for the quarter, compared to the consensus estimate of $5.28 billion. Fresenius Medical Care had a net margin of 2.72% and a return on equity of 5.48%. On average, equities analysts predict that Fresenius Medical Care AG will post 1.51 earnings per share for the current year.

Institutional Trading of Fresenius Medical Care

Several large investors have recently made changes to their positions in the stock. GAMMA Investing LLC grew its stake in Fresenius Medical Care by 21.8% in the 1st quarter. GAMMA Investing LLC now owns 4,230 shares of the company’s stock valued at $82,000 after buying an additional 758 shares during the last quarter. Assetmark Inc. grew its position in shares of Fresenius Medical Care by 169.9% in the fourth quarter. Assetmark Inc. now owns 4,178 shares of the company’s stock valued at $87,000 after purchasing an additional 2,630 shares during the last quarter. ORG Partners LLC bought a new position in shares of Fresenius Medical Care in the first quarter worth about $110,000. SageView Advisory Group LLC acquired a new position in shares of Fresenius Medical Care during the 1st quarter worth about $127,000. Finally, Signaturefd LLC boosted its stake in Fresenius Medical Care by 8.4% during the 2nd quarter. Signaturefd LLC now owns 8,713 shares of the company’s stock valued at $166,000 after purchasing an additional 672 shares during the period. Institutional investors own 8.25% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.